cancer cell-2016-A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
本文檔由 Science 分享于2016-01-13 19:35
暫無簡介
本文檔由 Science 分享于2016-01-13 19:35
手機或平板掃掃即可繼續(xù)訪問
推薦豆丁書房APP 掃掃更高清